From: The effect of smoking on biological change of recurrent breast cancer
Parameters | Estrogen receptor | p value | Progesterone receptor | p value | HER2 | p value | |||
---|---|---|---|---|---|---|---|---|---|
Negative conversion (n = 3) | The other (n = 47) | Negative Conversion (n = 15) | No change (n = 35) | Positive Conversion (n = 6) | No change (n = 44) | ||||
Age at operation (years old) | |||||||||
 ≤ 60 | 1 (33.3%) | 25 (53.2%) | 0.514 | 7 (46.7%) | 19 (54.3%) | 0.63 | 4 (66.7%) | 22 (50.0%) | 0.453 |
 > 60 | 2 (66.7%) | 22 (46.8%) | 8 (53.3%) | 16 (45.7%) |  | 2 (33.3%) | 22 (50.0%) | ||
Tumor size (mm) | |||||||||
 ≤ 21.8 | 1 (33.3%) | 24 (51.1%) | 0.561 | 10 (66.7%) | 15 (42.9%) | 0.128 | 4 (66.7%) | 21 (47.7%) | 0.394 |
 > 21.8 | 2 (66.7%) | 23 (48.9%) | 5 (33.3%) | 20 (57.1%) |  | 2 (33.3%) | 23 (52.3%) | ||
Lymph node metastasis | |||||||||
 Negative | 2 (66.7%) | 41 (87.2%) | 0.33 | 12 (80.0%) | 31 (88.6%) | 0.434 | 6 (100.0%) | 37 (84.1%) | 0.302 |
 Positive | 1 (33.3%) | 6 (12.8%) | 3 (20.0%) | 4 (11.4%) |  | 0 (0.0%) | 7 (15.9%) | ||
Ki67 of primary tumor | |||||||||
 ≤ 14% | 2 (66.7%) | 17 (36.2%) | 0.301 | 5 (33.3%) | 14 (40.0%) | 0.664 | 1 (16.7%) | 18 (40.9%) | 0.26 |
 > 14% | 1 (33.3%) | 30 (63.8%) | 10 (66.7%) | 21 (60.0%) | 5 (83.3%) | 26 (59.1%) | |||
Chemotherapy after surgery | |||||||||
 No | 1 (33.3%) | 36 (76.6%) | 0.102 | 11 (73.3%) | 26 (74.3%) | 0.945 | 5 (83.3%) | 32 (72.7%) | 0.588 |
 Yes | 2 (66.7%) | 11 (23.4%) | 4 (26.7%) | 9 (25.7%) | 1 (16.7%) | 12 (27.3%) | |||
Endocrine therapy after surgery | |||||||||
 No | 1 (33.3%) | 13 (27.7%) | 0.836 | 0 (0.0%) | 14 (40.0%) | 0.003 | 2 (33.3%) | 12 (27.3%) | 0.762 |
 Yes | 2 (66.7%) | 34 (72.3%) | 15 (100.0%) | 21 (60.0%) | 4 (66.7%) | 32 (72.7%) | |||
Radiation therapy after surgery | |||||||||
 No | 1 (33.3%) | 38 (80.9%) | 0.056 | 10 (66.7%) | 29 (82.9%) | 0.213 | 5 (83.3%) | 34 (77.3%) | 0.743 |
 Yes | 2 (66.7%) | 9 (19.1%) | 5 (33.3%) | 6 (17.1%) | 1 (16.7%) | 10 (22.7%) | |||
Trastuzumab after surgery | |||||||||
 No | 3 (100.0%) | 46 (97.9%) | 0.804 | 15 (100.0%) | 34 (97.1%) | 0.518 | 6 (100.0%) | 43 (97.7%) | 0.716 |
 Yes | 0 (0.0%) | 1 (2.1%) | 0 (0.0%) | 1 (2.9%) | 0 (0.0%) | 1 (2.3%) | |||
No-treatment after surgery | |||||||||
 No | 3 (100.0%) | 41 (87.2%) | 0.519 | 15 (100.0%) | 29 (82.9%) | 0.091 | 5 (83.3%) | 39 (88.6%) | 0.715 |
 Yes | 0 (0.0%) | 6 (12.8%) | 0 (0.0%) | 6 (17.1%) | 1 (16.7%) | 5 (11.4%) | |||
Age at recurrence (years old) | |||||||||
 ≤ 62 | 1 (33.3%) | 25 (53.2%) | 0.514 | 8 (53.3%) | 18 (51.4%) | 0.904 | 4 (66.7%) | 22 (50.0%) | 0.454 |
 > 62 | 2 (66.7%) | 22 (46.8%) | 7 (46.7%) | 17 (48.6%) | 2 (33.3%) | 22 (50.0%) | |||
Recurrence site biopsied | |||||||||
 Local, regional lymph node | 2 (66.7%) | 43 (91.5%) | 0.25 | 14 (93.3%) | 31 (88.6%) | 0.458 | 6 (100.0%) | 39 (88.6%) | 0.715 |
 Distant metastasis | 1 (33.3%) | 4 (8.5%) | 1 (6.7%) | 4 (11.4%) | 0 (0.0%) | 5 (11.4%) | |||
Change of ER in recurrence | |||||||||
 Negative conversion | – | – | – | 2 (13.3%) | 1 (2.9%) | 0.159 | 0 (0.0%) | 3 (6.8%) | 0.519 |
 The other | – | – | 13 (86.7%) | 34 (97.1%) | 6 (100.0%) | 41 (93.2%) | |||
Change of PgR in recurrence | |||||||||
 Negative conversion | 2 (66.7%) | 13 (27.7%) | 0.159 | – | – | – | 3 (50.0%) | 12 (27.3%) | 0.264 |
 No change | 1 (33.3%) | 34 (72.3%) | – | – | 3 (50.0%) | 32 (72.7%) | |||
Change of HER2 in recurrence | |||||||||
 Positive conversion | 0 (0.0%) | 6 (12.8%) | 0.519 | 3 (20.0%) | 3 (8.6%) | 0.264 | – | – | – |
 No change | 3 (100.0%) | 41 (87.2%) | 12 (80.0%) | 34 (91.4%) | – | – | |||
Disease free survival | |||||||||
 ≤ 792 | 2 (66.7%) | 23 (48.9%) | 0.561 | 8 (53.3%) | 17 (48.6%) | 0.764 | 3 (50.0%) | 22 (50.0%) | 1 |
 > 792 | 1 (33.3%) | 24 (51.1%) | 7 (46.7%) | 18 (51.4%) | 3 (50.0%) | 22 (50.0%) |